RESULTS OF A PHASE 1 STUDY OF BMN 673, A POTENT AND SPECIFIC PARP-1/2 INHIBITOR, IN PATIENTS WITH ADVANCED HEMATOLOGICAL MALIGNANCIES

被引：0
|
作者：
Mufti, G. J. [1 ]
Estey, E. [2 ]
Popat, R. [3 ]
Mattison, R. [4 ]
Menne, T. [5 ]
Azar, J. [6 ]
Bloor, A. [7 ]
Gaymes, T. [1 ]
Khwaja, A. [3 ]
Juckett, M. [4 ]
Lennard, A. [5 ]
Zhang, C. [8 ]
Gallant, G. J. A. [8 ]
Gopal, A. K. [2 ]
机构：
[1] Kings Coll Hosp NHS Fdn Trust, London, England
[2] Univ Washington, Seattle Canc Care Alliance, Seattle, WA 98195 USA
[3] UCL, Inst Canc, London, England
[4] Univ Wisconsin, Madison, WI USA
[5] Newcastle Upon Tyne NHS Fdn Trust, Newcastle Upon Tyne, Tyne & Wear, England
[6] Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA
[7] Christie Hosp NHS Trust, Manchester, Lancs, England
[8] BioMarin Pharmaceut Inc, Novato, CA USA
来源：
HAEMATOLOGICA | 2014年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P180
引用
收藏
页码：33 / 34
页数：2
相关论文
共 50 条
  • [1] Inhibition of PBMC PARP activity with the novel PARP 1/2 inhibitor BMN 673 in patients with advanced solid tumors
    Henshaw, Joshua W.
    Zhou, Huiyu
    Herriott, Ashleigh
    Patterson, Miranda
    Wang, Evelyn W.
    Musson, Don
    de Bono, Johann
    Mina, Lida A.
    Ramanathan, Ramesh K.
    O'Neill, Charles
    Dorr, Andrew
    Curtin, Nicola J.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [2] Safety and efficacy results from a phase 1 dose-escalation trial of the parp inhibitor talazoparib (bmn-673) in combination with either temozolomide or irinotecan in patients with advanced malignancies
    Wainberg, Z. A.
    Hecht, J. R.
    Konecny, G. E.
    Chmielowski, B.
    Finn, R. S.
    Martinez, D.
    Yonemoto, L.
    Glaspy, J.
    Slamon, D. J.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S60 - S60
  • [3] A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer
    Tuli, R.
    Shiao, S. L.
    Nissen, N.
    Tighiouart, M.
    Kim, S.
    Osipov, A.
    Bryant, M.
    Ristow, L.
    Placencio-Hickok, V. R.
    Hoffman, D.
    Rokhsar, S.
    Scher, K.
    Klempner, S. J.
    Noe, P.
    Davis, M. J.
    Wachsman, A.
    Lo, S.
    Jamil, L.
    Sandler, H.
    Piantadosi, S.
    Hendifar, A.
    EBIOMEDICINE, 2019, 40 : 375 - 381
  • [4] BMN673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency
    Shen, Yuqiao
    Rehman, Farah L.
    Feng, Ying
    Boshuizen, Julia
    Bajrami, Ilirjana
    Elliott, Richard
    Wang, Bing
    Lord, Christopher J.
    Post, Leonard E.
    Ashworth, Alan
    CLINICAL CANCER RESEARCH, 2013, 19 (18) : 5003 - 5015
  • [5] BMN 673 is a PARP inhibitor in clinical development for the treatment of breast cancer patients with deleterious germline BRCA 1 and 2 mutations
    Mina, L. A.
    Ramanathan, R. K.
    Wainberg, Z. A.
    Byers, L. A.
    Chugh, R.
    Sachdev, J. C.
    Matei, D.
    Zhang, C.
    Henshaw, J. W.
    Dorr, A.
    Kaye, S. B.
    de Bono, J. S.
    CANCER RESEARCH, 2013, 73
  • [6] HYDAMTIQ: A new, potent PARP-1 inhibitor with neuroprotective properties
    Pellicciari, Roberto
    Gioiello, Antimo
    Camaioni, Emidio
    Macchiarulo, Antonio
    Gilbert, Adam
    Bikker, Jack
    Costantino, Gabriele
    Robertson, Graeme Michael
    Venturoni, Francesco
    Carotti, Andrea
    Bellocchi, Daniele
    Cozzi, Andrea
    Wood, Andrew
    Gonzales, Cathleen
    Zaleska, Margaret
    Ellingboe, John
    Flavio, Moroni
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 241
  • [7] The effect of food on the oral bioavailability of the novel PARP 1/2 inhibitor BMN 673 in healthy male subjects
    Henshaw, Joshua
    Zhou, Huiyu
    Musson, Don
    O'Neill, Charles
    Stoltz, Randall
    Dorr, Andrew
    CANCER RESEARCH, 2014, 74 (19)
  • [8] Initial Testing (Stage 1) of the PARP Inhibitor BMN 673 by the Pediatric Preclinical Testing Program: PALB2 Mutation Predicts Exceptional In Vivo Response to BMN 673
    Smith, Malcolm A.
    Hampton, Oliver A.
    Reynolds, C. Patrick
    Kang, Min H.
    Maris, John M.
    Gorlick, Richard
    Kolb, E. Anders
    Lock, Richard
    Carol, Hernan
    Keir, Stephen T.
    Wu, Jianrong
    Kurmasheva, Raushan T.
    Wheeler, David A.
    Houghton, Peter J.
    PEDIATRIC BLOOD & CANCER, 2015, 62 (01) : 91 - 98
  • [9] PARP inhibitor BMN-673 induced apoptosis by trapping PARP-1 and inhibiting base excision repair via modulation of pol-β in chromatin of breast cancer cells
    Sethy, Chinmayee
    Kundu, Chanakya Nath
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2022, 436
  • [10] A phase 2, 2-stage, 2-cohort study of the oral PARP inhibitor BMN 673 in patients with germline BRCA mutation and locally advanced and/or metastatic breast cancer (ABRAZO study)
    Turner, Nicholas C.
    Balmana, Judith
    Domchek, Susan M.
    Visco, Frances
    Zhang, Charlie
    Lokker, Nathalie A.
    Lounsbury, Debra L.
    Robson, Mark E.
    CANCER RESEARCH, 2015, 75
12345